top of page


Our Core Technologies

We discovered glycolipid-antigens specific to the mycoplasma membrane, and have succeeded in the synthesis of antibodies at a commercial scale.

M Bio Technology holds international patents for this core technology (substance patents and vaccine manufacturing patents)

Discovery of an antigen specific to the membrane structure of mycoplasma bacteria

Since mycoplasma are the smallest of bacteria, it has not been possible to identify a specific antigen on its cell membrane. However, building on more than 30 years of research, we have finally discovered glycolipid-antigens that are specific to mycoplasma membranes.

Oligolipid with cell membrane.png

We succeeded in structural analysis and chemical synthesis of the antibody

With extensive research and joint projects, we fully identified the structure of the glycolipid-antibodies and have succeeded in optimizing the chemical synthesis of antibodies for high quality large-scale productions.


This novel discovery alters the prospective path to diagnosis (MID Prism), therapeutics and prevention (including vaccine development) for Mycoplasma Infections Diseases.

Synthesised antigen.png

About Our Portfolio

Discovery of glycolipid-antigens specific to the mycoplasma membrane, and successful chemical synthesis of the antibody at a commercial scale.

M. pneumoniae
M. fermentans
Technology: 動画
20140307 M Bio Technology Inc. マイコプラズマ脂質

MID Prism (Diagnosis)

"Mycoplasma lipid antigen" was originally discovered by M Bio Technology and successfully synthesized. We have already established an antigen-antibody test method to measure IgM, IgG, and IgA antibody titers individually.

The diagnostic method based on the antigen-antibody reaction (ELISA method) of mycoplasma has been established for a long time, but its sensitivity has never been high. This is because the antigen used in the test kit uses cell membranes and peptides extracted from natural mycoplasma. The test is composed of a « non-uniform material system » and the test accuracy is limited. After 30 years of research, M Bio Technology has successfully identified and chemically synthesized a mycoplasma-specific lipid antigen (glocolipid-antigen) and patented it. The "mycoplasma lipid antigen antibody test" that we have developed is chemically synthesized. It uses high fidelity antigens guaranteeing extremely high uniformity and reproducibility. Although limited to Japan, this diagnostic method has already been used at designated institutions. This method  can measure the presence or absence of two types of mycoplasma infection, mycoplasma pneumoniae and mycoplasma fermentas .

MID vaccine

We have established vaccine technology using "mycoplasma pseudoparticles", which are chemically synthesized with the exact same antigen as the natural mycoplasma lipid antigen

For the first time in the world, we are developing a new concept vaccine that has high therapeutic and preventive effects on mycoplasma infection which has been tested for safety. Mycoplasma mimic particles, which are chemically synthesized glycolipid antigens (glycolipid-antigen) present on the cell membrane, are administered into the body to promote an immune reaction and produce antibodies. In addition to this prophylactic process of obtaining immunity against infectious diseases, immuno-therapy-like applications that induce monoclonal antibodies to be used as therapeutic agents in bioreactors are being developed together with pharmaceutical companies. M Bio Technology holds a series of patents for identification of chemically identified glycolipid antigens, chemical synthesis, and production of simulated mycoplasma particles. In addition to joint development, M Bio Technology is also negotiating license out.

Vaccine concept BSJ.png
MID antibody image.png

MID antibodies

We have also succeeded in producing a monoclonal antibody specific to mycoplasma by further developing the MID vaccine technology. We are continuing to develop the world's first antibody drug for mycoplasma.

We are developing the basic technology to obtain a large amount of monoclonal antibody by introducing artificially synthesized "mycoplasma mimicking particles" into a bioreactor. We have already completed the production of antibodies for mycoplasma pneumoniae and mycoplasma fermentas , and characterized the antibody production mechanism. In the future, we will carry out joint development and clinical trials with pharmaceutical companies with the aim of having the world's first antibody drug for mycoplasma infection approved. 

About Our Portfolio

CEO presentation on BIO-Europe Spring Digital
March 2021

bottom of page